First-ever rapid-acting insulin. This approval extends to a 3-milliliter single-patient-use prefilled pen and a 10-milliliter ...
The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...
Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.
The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart), for improving glycemic control ...
Doctors developed it several decades ago as a guide to insulin dosage. Clinical guidelines typically recommend against using sliding scale insulin as the sole method of insulin management.
According to the FDA, the medication quickly helps to lower mealtime blood sugar spikes to improve control of blood sugar in ...
The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and ...
FDA approves third insulin biosimilar Merilog to ease U.S. supply shortage FDAs latest insulin biosimilar approval aims to mitigate ongoing supply challenges in the U.S.
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.